{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:03:39Z","timestamp":1793232219016,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009863","name":"Neuroendocrine Tumor Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009863","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005567","name":"H. Lee Moffitt Cancer Center and Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005567","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30-CA076292"],"award-info":[{"award-number":["P30-CA076292"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00259-021-05315-1","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T23:02:20Z","timestamp":1616799740000},"page":"3408-3421","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Preclinical evaluation of [225Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms"],"prefix":"10.1007","volume":"48","author":[{"given":"Narges K.","family":"Tafreshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darpan N.","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Tichacek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikalai M.","family":"Budzevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan N.","family":"Reff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Engelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Boulware","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto A.","family":"Chiappori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan R.","family":"Strosberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thaddeus J.","family":"Wadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghassan","family":"El-Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6006-7528","authenticated-orcid":false,"given":"David L.","family":"Morse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,26]]},"reference":[{"issue":"12","key":"5315_CR1","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.neo.2017.09.002","volume":"19","author":"B Oronsky","year":"2017","unstructured":"Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing But NET: A review of neuroendocrine tumors and carcinomas. Neoplasia. 2017;19(12):991\u20131002. https:\/\/doi.org\/10.1016\/j.neo.2017.09.002.","journal-title":"Neoplasia."},{"issue":"3","key":"5315_CR2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jtho.2016.11.2222","volume":"12","author":"AE Hendifar","year":"2017","unstructured":"Hendifar AE, Marchevsky AM, Tuli R. Neuroendocrine tumors of the lung: current challenges and advances in the diagnosis and management of well-differentiated disease. J Thorac Oncol. 2017;12(3):425\u201336. https:\/\/doi.org\/10.1016\/j.jtho.2016.11.2222.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"5315_CR3","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1043\/2009-0583-RAR.1","volume":"134","author":"N Rekhtman","year":"2010","unstructured":"Rekhtman N. Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med. 2010;134(11):1628\u201338. https:\/\/doi.org\/10.1043\/2009-0583-RAR.1.","journal-title":"Arch Pathol Lab Med"},{"issue":"15_suppl","key":"5315_CR4","doi-asserted-by":"publisher","first-page":"TPS4153","DOI":"10.1200\/jco.2012.30.15_suppl.tps4153","volume":"30","author":"P Delavault","year":"2012","unstructured":"Delavault P, Caplin ME, Liyange N, Blumberg J, UK, Society INTSENT. The CLARINET study: assessing the effect of lanreotide autogel on tumor progression-free survival in patients with nonfunctioning gastroenteropancreatic neuroendocrine tumors. Journal of Clinical Oncology. 2012;30(15_suppl):TPS4153\u2013TPS. https:\/\/doi.org\/10.1200\/jco.2012.30.15_suppl.tps4153.","journal-title":"Journal of Clinical Oncology"},{"issue":"28","key":"5315_CR5","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656\u201363. https:\/\/doi.org\/10.1200\/JCO.2009.22.8510.","journal-title":"J Clin Oncol"},{"issue":"2","key":"5315_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med"},{"issue":"25","key":"5315_CR7","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1200\/JCO.2018.78.5865","volume":"36","author":"J Strosberg","year":"2018","unstructured":"Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, et al. Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with (177)Lu-Dotatate in the phase III NETTER-1 trial. J Clin Oncol. 2018;36(25):2578\u201384. https:\/\/doi.org\/10.1200\/JCO.2018.78.5865.","journal-title":"J Clin Oncol"},{"issue":"10022","key":"5315_CR8","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JC Yao","year":"2016","unstructured":"Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022):968\u201377. https:\/\/doi.org\/10.1016\/S0140-6736(15)00817-X.","journal-title":"Lancet."},{"key":"5315_CR9","doi-asserted-by":"publisher","unstructured":"Lamberti G, Brighi N, Maggio I, Manuzzi L, Peterle C, Ambrosini V, et al. The role of mTOR in neuroendocrine tumors: future cornerstone of a winning strategy? Int J Mol Sci. 2018;19(3). https:\/\/doi.org\/10.3390\/ijms19030747.","DOI":"10.3390\/ijms19030747"},{"issue":"10","key":"5315_CR10","doi-asserted-by":"publisher","first-page":"12991","DOI":"10.1007\/s13277-016-5258-9","volume":"37","author":"G Lo Russo","year":"2016","unstructured":"Lo Russo G, Pusceddu S, Prinzi N, Imbimbo M, Proto C, Signorelli D, et al. Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors. Tumour Biol. 2016;37(10):12991\u20133003. https:\/\/doi.org\/10.1007\/s13277-016-5258-9.","journal-title":"Tumour Biol"},{"issue":"2","key":"5315_CR11","doi-asserted-by":"publisher","first-page":"278","DOI":"10.2214\/AJR.18.19953","volume":"211","author":"ES Mittra","year":"2018","unstructured":"Mittra ES. Neuroendocrine tumor therapy: (177)Lu-DOTATATE. AJR Am J Roentgenol. 2018;211(2):278\u201385. https:\/\/doi.org\/10.2214\/AJR.18.19953.","journal-title":"AJR Am J Roentgenol"},{"issue":"11","key":"5315_CR12","doi-asserted-by":"publisher","first-page":"e457","DOI":"10.1097\/RLU.0000000000001816","volume":"42","author":"S Ballal","year":"2017","unstructured":"Ballal S, Yadav MP, Damle NA, Sahoo RK, Bal C. Concomitant 177Lu-DOTATATE and capecitabine therapy in patients with advanced neuroendocrine tumors: a long-term-outcome, toxicity, survival, and quality-of-life study. Clin Nucl Med. 2017;42(11):e457\u2013e66. https:\/\/doi.org\/10.1097\/RLU.0000000000001816.","journal-title":"Clin Nucl Med"},{"issue":"12","key":"5315_CR13","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1007\/s00259-011-1902-1","volume":"38","author":"L Bodei","year":"2011","unstructured":"Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with (1)(7)(7)Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38(12):2125\u201335. https:\/\/doi.org\/10.1007\/s00259-011-1902-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"5315_CR14","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1159\/000494760","volume":"108","author":"S Navalkissoor","year":"2019","unstructured":"Navalkissoor S, Grossman A. Targeted alpha particle therapy for neuroendocrine tumours: the next generation of peptide receptor radionuclide therapy. Neuroendocrinology. 2019;108(3):256\u201364. https:\/\/doi.org\/10.1159\/000494760.","journal-title":"Neuroendocrinology."},{"issue":"1A","key":"5315_CR15","first-page":"409","volume":"21","author":"H Andersson","year":"2001","unstructured":"Andersson H, Palm S, Lindegren S, Back T, Jacobsson L, Leser G, et al. Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer. Anticancer Res. 2001;21(1A):409\u201312.","journal-title":"Anticancer Res"},{"issue":"11","key":"5315_CR16","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1158\/1078-0432.CCR-07-4647","volume":"14","author":"M Miederer","year":"2008","unstructured":"Miederer M, Henriksen G, Alke A, Mossbrugger I, Quintanilla-Martinez L, Senekowitsch-Schmidtke R, et al. Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors. Clin Cancer Res. 2008;14(11):3555\u201361. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-4647.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"5315_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1089\/108497804323071904","volume":"19","author":"D Milenic","year":"2004","unstructured":"Milenic D, Garmestani K, Dadachova E, Chappell L, Albert P, Hill D, et al. Radioimmunotherapy of human colon carcinoma xenografts using a 213Bi-labeled domain-deleted humanized monoclonal antibody. Cancer Biother Radiopharm. 2004;19(2):135\u201347. https:\/\/doi.org\/10.1089\/108497804323071904.","journal-title":"Cancer Biother Radiopharm"},{"issue":"23","key":"5315_CR18","doi-asserted-by":"publisher","first-page":"8941","DOI":"10.1158\/0008-5472.CAN-09-1828","volume":"69","author":"H Song","year":"2009","unstructured":"Song H, Hobbs RF, Vajravelu R, Huso DL, Esaias C, Apostolidis C, et al. Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y. Cancer Res. 2009;69(23):8941\u20138. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-1828.","journal-title":"Cancer Res"},{"issue":"3","key":"5315_CR19","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1158\/0008-5472.CAN-10-1186","volume":"71","author":"D Wild","year":"2011","unstructured":"Wild D, Frischknecht M, Zhang H, Morgenstern A, Bruchertseifer F, Boisclair J, et al. Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN). Cancer Res. 2011;71(3):1009\u201318. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-1186.","journal-title":"Cancer Res"},{"key":"5315_CR20","doi-asserted-by":"publisher","unstructured":"Tafreshi NK, Doligalski ML, Tichacek CJ, Pandya DN, Budzevich MM, El-Haddad G, et al. Development of targeted alpha particle therapy for solid tumors. Molecules. 2019;24(23). https:\/\/doi.org\/10.3390\/molecules24234314.","DOI":"10.3390\/molecules24234314"},{"issue":"2","key":"5315_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1089\/cbr.2016.2155","volume":"32","author":"J Nonnekens","year":"2017","unstructured":"Nonnekens J, Chatalic KL, Molkenboer-Kuenen JD, Beerens CE, Bruchertseifer F, Morgenstern A, et al. (213)Bi-labeled prostate-specific membrane antigen-targeting agents induce DNA double-Strand breaks in prostate cancer xenografts. Cancer Biother Radiopharm. 2017;32(2):67\u201373. https:\/\/doi.org\/10.1089\/cbr.2016.2155.","journal-title":"Cancer Biother Radiopharm"},{"issue":"4","key":"5315_CR22","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1007\/s00259-019-04567-2","volume":"47","author":"S Ballal","year":"2020","unstructured":"Ballal S, Yadav MP, Bal C, Sahoo RK, Tripathi M. Broadening horizons with (225)Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to (177)Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety. Eur J Nucl Med Mol Imaging. 2020;47(4):934\u201346. https:\/\/doi.org\/10.1007\/s00259-019-04567-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"5315_CR23","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1007\/s00259-006-0172-9","volume":"33","author":"JP Esser","year":"2006","unstructured":"Esser JP, Krenning EP, Teunissen JJ, Kooij PP, van Gameren AL, Bakker WH, et al. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging. 2006;33(11):1346\u201351. https:\/\/doi.org\/10.1007\/s00259-006-0172-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"5315_CR24","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/s0969-8043(01)00062-8","volume":"55","author":"D Ma","year":"2001","unstructured":"Ma D, McDevitt MR, Finn RD, Scheinberg DA. Breakthrough of 225Ac and its radionuclide daughters from an 225Ac\/213Bi generator: development of new methods, quantitative characterization, and implications for clinical use. Appl Radiat Isot. 2001;55(5):667\u201378. https:\/\/doi.org\/10.1016\/s0969-8043(01)00062-8.","journal-title":"Appl Radiat Isot"},{"issue":"3","key":"5315_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3934\/medsci.2015.3.228","volume":"2","author":"K Yong","year":"2015","unstructured":"Yong K, Brechbiel M. Application of (212)Pb for targeted alpha-particle therapy (TAT): pre-clinical and mechanistic understanding through to clinical translation. AIMS Med Sci. 2015;2(3):228\u201345. https:\/\/doi.org\/10.3934\/medsci.2015.3.228.","journal-title":"AIMS Med Sci"},{"issue":"16","key":"5315_CR26","first-page":"5084","volume":"63","author":"PE Borchardt","year":"2003","unstructured":"Borchardt PE, Yuan RR, Miederer M, McDevitt MR, Scheinberg DA. Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res. 2003;63(16):5084\u201390.","journal-title":"Cancer Res"},{"issue":"1","key":"5315_CR27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1134\/S1066362211010103","volume":"53","author":"BL Zhuikov","year":"2011","unstructured":"Zhuikov BL, Kalmykov SN, Ermolaev RA, Aliev VM, Kokhanyuk VL, Matushko IG, et al. Production of 225Ac and 223Ra by irradiation of Th with accelerated protons. Radiochemistry. 2011;53(1):77\u201380.","journal-title":"Radiochemistry."},{"key":"5315_CR28","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.apradiso.2016.09.026","volume":"118","author":"JR Griswold","year":"2016","unstructured":"Griswold JR, Medvedev DG, Engle JW, Copping R, Fitzsimmons JM, Radchenko V, et al. Large scale accelerator production of (225)Ac: effective cross sections for 78-192MeV protons incident on (232)Th targets. Appl Radiat Isot. 2016;118:366\u201374. https:\/\/doi.org\/10.1016\/j.apradiso.2016.09.026.","journal-title":"Appl Radiat Isot"},{"key":"5315_CR29","unstructured":"John K, editor. Targeted Alpha Therapy: The US DOE Tri-Lab (ORNL, BNL, LANL) Research Effort to Provide Accelerator-Produced 225Ac for Radiotherapy. American Physical Society Annual Meeting; 2017 January 2017; New Orleans, LA USA."},{"key":"5315_CR30","unstructured":"Reid Y, Storts D, Riss T, Minor L. Authentication of human cell lines by STR DNA profiling analysis. In: Sittampalam GS, Coussens NP, Brimacombe K, Grossman A, Arkin M, Auld D et al., editors. Assay Guidance Manual. Bethesda (MD)2004."},{"issue":"3","key":"5315_CR31","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1158\/0008-5472.CAN-10-3091","volume":"71","author":"NK Tafreshi","year":"2011","unstructured":"Tafreshi NK, Enkemann SA, Bui MM, Lloyd MC, Abrahams D, Huynh AS, et al. A mammaglobin-a targeting agent for noninvasive detection of breast cancer metastasis in lymph nodes. Cancer Res. 2011;71(3):1050\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-3091.","journal-title":"Cancer Res"},{"issue":"23","key":"5315_CR32","doi-asserted-by":"publisher","first-page":"8078","DOI":"10.1021\/jm201226w","volume":"54","author":"NM Barkey","year":"2011","unstructured":"Barkey NM, Tafreshi NK, Josan JS, De Silva CR, Sill KN, Hruby VJ, et al. Development of melanoma-targeted polymer micelles by conjugation of a melanocortin 1 receptor (MC1R) specific ligand. J Med Chem. 2011;54(23):8078\u201384. https:\/\/doi.org\/10.1021\/jm201226w.","journal-title":"J Med Chem"},{"issue":"5","key":"5315_CR33","doi-asserted-by":"publisher","first-page":"698","DOI":"10.7150\/thno.14338","volume":"6","author":"DN Pandya","year":"2016","unstructured":"Pandya DN, Hantgan R, Budzevich MM, Kock ND, Morse DL, Batista I, et al. Preliminary therapy evaluation of (225)Ac-DOTA-c(RGDyK) demonstrates that Cerenkov radiation derived from (225)Ac daughter decay can be detected by optical imaging for in vivo tumor visualization. Theranostics. 2016;6(5):698\u2013709. https:\/\/doi.org\/10.7150\/thno.14338.","journal-title":"Theranostics."},{"issue":"8","key":"5315_CR34","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.2967\/jnumed.118.217240","volume":"60","author":"NK Tafreshi","year":"2019","unstructured":"Tafreshi NK, Tichacek CJ, Pandya DN, Doligalski ML, Budzevich MM, Kil H, et al. Melanocortin 1 receptor-targeted alpha-particle therapy for metastatic uveal melanoma. J Nucl Med. 2019;60(8):1124\u201333. https:\/\/doi.org\/10.2967\/jnumed.118.217240.","journal-title":"J Nucl Med"},{"issue":"1","key":"5315_CR35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ab.2005.03.034","volume":"342","author":"DL Morse","year":"2005","unstructured":"Morse DL, Carroll D, Weberg L, Borgstrom MC, Ranger-Moore J, Gillies RJ. Determining suitable internal standards for mRNA quantification of increasing cancer progression in human breast cells by real-time reverse transcriptase polymerase chain reaction. Anal Biochem. 2005;342(1):69\u201377. https:\/\/doi.org\/10.1016\/j.ab.2005.03.034.","journal-title":"Anal Biochem"},{"key":"5315_CR36","doi-asserted-by":"crossref","unstructured":"Morss LR, Edelstein N, Fuger J, Katz JJ. The chemistry of the actinide and transactinide elements, Volumes 1\u20136. In: Morss LR, Edelstein, N., Fuger, J., Katz, J.J., editor. 4th ed: Springer Science and Business Media; 2011.","DOI":"10.1007\/978-94-007-0211-0"},{"key":"5315_CR37","doi-asserted-by":"publisher","unstructured":"Tichacek CJ, Budzevich MM, Wadas TJ, Morse DL, Moros EG. A Monte Carlo method for determining the response relationship between two commonly used detectors to indirectly measure alpha particle radiation activity. Molecules. 2019;24(18). doi:https:\/\/doi.org\/10.3390\/molecules24183397.","DOI":"10.3390\/molecules24183397"},{"issue":"5","key":"5315_CR38","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1667\/rr3105","volume":"161","author":"B Lambert","year":"2004","unstructured":"Lambert B, Cybulla M, Weiner SM, Van De Wiele C, Ham H, Dierckx RA, et al. Renal toxicity after radionuclide therapy. Radiat Res. 2004;161(5):607\u201311. https:\/\/doi.org\/10.1667\/rr3105.","journal-title":"Radiat Res"},{"issue":"7","key":"5315_CR39","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2967\/jnumed.110.075101","volume":"51","author":"E Vegt","year":"2010","unstructured":"Vegt E, de Jong M, Wetzels JF, Masereeuw R, Melis M, Oyen WJ, et al. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med. 2010;51(7):1049\u201358. https:\/\/doi.org\/10.2967\/jnumed.110.075101.","journal-title":"J Nucl Med"},{"issue":"1","key":"5315_CR40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00259-002-0982-3","volume":"30","author":"EJ Rolleman","year":"2003","unstructured":"Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging. 2003;30(1):9\u201315. https:\/\/doi.org\/10.1007\/s00259-002-0982-3.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05315-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-021-05315-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05315-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T05:04:56Z","timestamp":1631595896000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-021-05315-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,26]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["5315"],"URL":"https:\/\/doi.org\/10.1007\/s00259-021-05315-1","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,26]]},"assertion":[{"value":"5 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Drs. Morse and Wadas are co-inventors on a provisional patent application. No other potential conflicts of interest relevant to this article exist.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}